Form 6-K EUPRAXIA PHARMACEUTICALS For: May 12

May 12, 2026 5:07 PM EDT
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2026

Commission File Number 001-41923

 

 

EUPRAXIA PHARMACEUTICALS INC.

(Translation of registrant’s name into English)

 

 

2198 Yukon Street

Vancouver, British Columbia, Canada V5Y 3P1

Telephone: (250) 590-3968

(Address of principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☐   Form 40-F ☒

 

 

INCORPORATION BY REFERENCE

Exhibits 99.1 and 99.2 of this Form 6-K are incorporated by reference into the registrant’s Registration Statement on Form F-10 (File No. 333-276586) and the registrant’s Registration Statement on Form S-8 (File No. 333-278534).

 

 
 



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    Eupraxia Pharmaceuticals Inc.
Date: May 12, 2026     By:  

/s/ Alex Rothwell

      Name: Alex Rothwell
      Title: Chief Financial Officer

ATTACHMENTS / EXHIBITS

EX-99.1

EX-99.2

EX-99.3

EX-99.4

EX-99.5



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings